# A Study Evaluating the Safety, Tolerability of LPM3480226 Tablets in Patients With Advanced Solid Tumors

> **NCT03844438** · PHASE1 · UNKNOWN · sponsor: **Luye Pharma Group Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** LPM3480226

## Key facts

- **NCT ID:** NCT03844438
- **Lead sponsor:** Luye Pharma Group Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-12-18
- **Primary completion:** 2020-10-28
- **Final completion:** 2022-03-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2019-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03844438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03844438, "A Study Evaluating the Safety, Tolerability of LPM3480226 Tablets in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03844438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*